Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ACLY | P53396 | 18/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL426349 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL431228 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL27808233 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL426131 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL30464701 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL424027 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL168115 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL10629086 | 0.84 | ALDH1A1 (0.68) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL2024217 | 0.84 | ALDH1A1 (0.68) | ALDH1A1ACLYCPT2 | |
| Citric Acid SCHEMBL8903778 | 0.84 | ALDH1A1 (0.68) | ALDH1A1ACLYCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587635-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Evolved by Nature, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230203-A1 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024059862-A9 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20240408174-A1 | SILK STIMULATED COLLAGEN AND CLAUDIN-1 EXPRESSION, AND SILK STIMULATED ANTI-INFLAMMATORY EFFECTS | EVOLVED BY NATURE, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4419071-A1 | SILK STIMULATED COLLAGEN AND CLAUDIN-1 EXPRESSION, AND SILK STIMULATED ANTI-INFLAMMATORY EFFECTS | Evolved by Nature, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024059862-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023069956-A1 | SILK STIMULATED COLLAGEN AND CLAUDIN-1 EXPRESSION, AND SILK STIMULATED ANTI-INFLAMMATORY EFFECTS | EVOLVED BY NATURE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220401335-A1 | SILK HAIR CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220313590-A1 | SILK STIMULATED COLLAGEN PRODUCTION AND METHODS OF USE THEREOF | EVOLVED BY NATURE, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220287944-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE INC (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3979873-A1 | SILK STIMULATED COLLAGEN PRODUCTION AND METHODS OF USE THEREOF | Evolved by Nature, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3955886-A1 | SILK HAIR CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-1402875-A1 | POWDERY COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030202993-A1 | Powdery composition | SHISEIDO COMPANY, LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401335-A1 | SILK HAIR CARE COMPOSITIONS | CUTA, KRT18, MATR3 | ALDH1A1 3906/4885ACLY 1909/4885CPT2 2764/4885 |
| US-20030202993-A1 | Powdery composition | CUTA, FLNA, FERMT2 | ALDH1A1 3772/4885ACLY 496/4885CPT2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.